Edinburgh, UK, 04 July 2022 – RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter – announces the appointment of Alexandra Brownfield as Head of Business Development.
Alexandra joins RoslinCT as Head of Business Development in July 2022, having over 20 years of experience in the Biologics / ATMP CDMO space. She brings with her a wealth of experience and knowledge covering everything from sales to customer service and strategy development.
Alexandra has a background in Molecular Biology and has held a number of roles including Project Management, Associate Director of Proposals, Business Development Director and Head of Business Development. She will now oversee RoslinCT’s sales and marketing team and the overall commercial strategy, as well as being a key figure supporting the company’s growth plans.
Peter Coleman said: “It’s fantastic to have Alexandra join our strengthened senior management team. Having strong commercial leadership is crucial for our growth strategy and for identifying further opportunities that match our global ambitions. I’m confident that she will be a great asset as we continue to develop and grow the business.”
Alexandra Brownfield said: “It’s a privilege to be joining such a dynamic company in the cell and gene therapy field. RoslinCT has exhibited significant growth over recent years, and I am excited to be a part of the journey moving forwards.”
RoslinCT has now entered a new and exciting phase of growth alongside investors, GHO Capital Partners to become a global leader in the cell & gene therapy space building on the great science, capabilities and hard work so far. Since the investment from GHO, RoslinCT has already seen tremendous growth in the company and further building of the senior team. This puts RoslinCT in an even stronger position to continue to partner with existing and new customers and provide life-changing and life-saving cell therapies for our patients.
RoslinCT is a leading UK Cell Therapy Contract Development and Manufacturing Organisation (CDMO) focused on providing services for companies developing cell-based therapeutic products. Originally founded in 2006 as a spin-out from the Roslin Institute, we built on the broad range of scientific expertise available in the field of cell biology. Based at the Edinburgh BioQuarter, we operate fully licensed GMP manufacturing facilities and have a proven track record in the delivery of cell-based products. For further information, please visit www.roslinct.com.
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high-growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market-leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.